drugset / Trial / NCT03837756
Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
Phase 2
Completed
47 enrolled
University of Aarhus
Aalborg University Hospital · collabHvidovre University Hospital · collabOdense University Hospital · collabOslo University Hospital · collabRigshospitalet, Denmark · collabThe Peter Doherty Institute for Infection and Immunity · collabUniversity of Utah · collab
RandomizedFactorialDouble-blindTreatment
Summary
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir
Timeline
- Start
- 2019-05-06
- Primary completion
- 2022-07-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LAFUVITUG | Monoclonal antibody | — | — |
| Comparator | Zinlirvimab | Monoclonal antibody | — | — |
| Comparator | lefitolimod | Oligonucleotide (other) | — | Subcutaneous |